SCHEMBL6766210

SCHEMBL6766210

C/C(=C/C(=O)O)c1ccccc1Sc1ccc(Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
SIRT1 Q96EB6 1/20 0.47
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
SLC6A9 P48067 2/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 3/20 0.45
BLM P54132 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NOD2 Q9HC29 1/20 0.45
SLC6A4 P31645 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.42
BCL2L1 Q07817 1/20 0.42
RHEB Q15382 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766212 1.00 CHRM2 (0.49) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL2306567 0.83 CHRM2 (0.54) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL6761061 0.81 CHRM2 (0.55) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL6761062 0.81 CHRM2 (0.55) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL6781026 0.81 NPC1 (0.56) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL29216353 0.78 KMT2A (0.47) ALDH1A1MEN1KMT2AL3MBTL1POLB
SCHEMBL11334883 0.76 SIRT1 (0.74) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL8967852 0.74 NR4A1 (0.60) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL15284800 0.73 SIRT1 (0.47) CHRM2CHRM1CHRM3SIRT1HDAC1
SCHEMBL6763132 0.73 CHRM2 (0.40) CHRM2CHRM1CHRM3SLC6A9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 CHRM2 624/4885CHRM1 274/4885CHRM3 843/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 CHRM2 624/4885CHRM1 274/4885CHRM3 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.